At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 255 enrolled
Drug / intervention
Data Collectionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride
In Brief
A Phase 4 clinical trial evaluating Data Collection for Neoplasm Metastasis / Bone and Bones. Completed, enrolled 255 participants across 117 sites in 22 countries.
Detailed Summary
Patients will be followed up in this study after prior treatment with BAY88-8223 / Radium-223 dichloride / Xofigo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm Metastasis / Bone and Bones
CountriesAustralia, Belgium, Brazil, Canada, Czechia, Finland, France, Germany, Hong Kong, Israel, Italy, Japan, Norway, Poland, Russia, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartDec 2014
Primary CompletionJan 2024
TodayJul 2026
First PostedDec 9, 2014
Enrollment StartDec 18, 2014
Primary CompletionJan 31, 2024
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 11.6 years ago
Interventions
Data Collectionother
No study treatment will be provided in this long term follow up study.